Biocidal products

Draft Commission Implementing Decision not approving 2,2-Dibromo-2-cyanoacetamide (DBNPA) as an existing active substance for use in biocidal products of product-type 4 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council

This draft Commission Implementing Decision does not approve 2,2-Dibromo-2-cyanoacetamide (DBNPA) as an active substance for use in biocidal products of product-type 4.

DBNPA has endocrine disrupting properties that may cause adverse effects in humans and the environment (non-target organisms) in accordance with the criteria laid down in Commission Delegated Regulation (EU) 2017/2100. DBNPA therefore meets the exclusion criteria set out in Article 5(1), point (d), of Regulation (EU) No 528/2012. None of the derogation criteria under Article 5(2) of the BPR are considered met, alternatives are available for its use in biocidal products of product-type 4. It is therefore appropriate not to approve DBNPA for use in biocidal products of product-type 4.